← Leaderboards
Scott A Armstrong
Dana-Farber Cancer Institute
$21,470,003
Attributed
$26,627,335
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.5M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,883,176 · 15
By mechanism
U54$13,203,677 · 1
R01$11,416,992 · 4
P01$8,638,858 · 6
T32$3,745,060 · 1
RC2$3,425,234 · 1
P50$789,560 · 1
Top collaborators
- Jun Qi6 shared
- Charles David Allis5 shared
- Robert G Roeder5 shared
- Kimberly Stegmaier3 shared
- Ramesh A Shivdasani2 shared
- Benjamin Levine Ebert1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Kimberly Stegmaier$26,925,503
- James D Griffin$8,295,553
- Emily H Cheng$11,285,808
- Stanley J Korsmeyer$3,203,954
- Sandra S Zinkel$4,253,324
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionLeukemiaIn VivoProgramsCellsIn VitroTherapeutic TargetGenesMouse ModelEpigenetic ProcessDiagnosisSmall MoleculeProteinsBaseGenome-WideMemberMutantMll GeneClinical TrialsHematopoieticLeukemogenesisBiologicalDependencePathway Interactions
Grant awards (66)
Development of Novel Therapeutic Strategies in Human Leukemias$2,052,164
P01 · FY2025 · CA
Defining epigenetic mechanisms in NPM1c mutant leukemia$403,607
R01 · FY2025 · CA · contact PI
Defining mechanisms of action of Menin inhibition in AML$389,775
P01 · FY2025 · CA · contact PI
Research Training in Pediatric Oncology$533,976
T32 · FY2024 · CA · contact PI
Biology and therapeutic targeting of zinc finger transcription factors in AML$385,014
P01 · FY2024 · CA · contact PI
Defining epigenetic mechanisms in NPM1c mutant leukemia$383,426
R01 · FY2024 · CA · contact PI
Research Training in Pediatric Oncology$445,947
T32 · FY2023 · CA · contact PI
Biology and therapeutic targeting of zinc finger transcription factors in AML$396,699
P01 · FY2023 · CA · contact PI
Defining epigenetic mechanisms in NPM1c mutant leukemia$395,535
R01 · FY2023 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$505,427
U54 · FY2022 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$395,996
R01 · FY2022 · CA · contact PI
Defining epigenetic mechanisms in NPM1c mutant leukemia$395,535
R01 · FY2022 · CA · contact PI
Research Training in Pediatric Oncology$393,881
T32 · FY2022 · CA · contact PI
Biology and therapeutic targeting of zinc finger transcription factors in AML$391,080
P01 · FY2022 · CA · contact PI
Research Training in Pediatric Oncology$491,097
T32 · FY2021 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2021 · CA · contact PI
Defining epigenetic mechanisms in NPM1c mutant leukemia$403,607
R01 · FY2021 · CA · contact PI
Biology and therapeutic targeting of zinc finger transcription factors in AML$399,061
P01 · FY2021 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$198,250
U54 · FY2021 · CA
Targeting MLL/Menin in AML$20,549
P50 · FY2021 · CA · contact PI
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies$691,925
R01 · FY2020 · CA
Biology and therapeutic targeting of zinc finger transcription factors in AML$405,564
P01 · FY2020 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2020 · CA · contact PI
Research Training in Pediatric Oncology$378,385
T32 · FY2020 · CA · contact PI
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies$673,519
R01 · FY2019 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$391,951
R01 · FY2019 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$239,963
R01 · FY2019 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$12,500,000
U54 · FY2018 · CA
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies$698,696
R01 · FY2018 · CA
Research Training in Pediatric Oncology$491,462
T32 · FY2018 · CA · contact PI
Targeting DOT1L for Degradation in MLL-rearranged Leukemia$404,076
R01 · FY2018 · CA · contact PI
Targeting MLL/Menin in AML$348,122
P50 · FY2018 · CA · contact PI
Targeting MLL/Menin in AML$88,243
P50 · FY2018 · CA · contact PI
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies$701,584
R01 · FY2017 · CA
Research Training in Pediatric Oncology$538,819
T32 · FY2017 · CA · contact PI
Targeting MLL/Menin in AML$332,646
P50 · FY2017 · CA · contact PI
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies$721,245
R01 · FY2016 · CA
Research Training in Pediatric Oncology$471,493
T32 · FY2016 · CA · contact PI
Targeting to Epigenetic Modications in ALL$402,250
R01 · FY2016 · CA · contact PI
Targeting to Epigenetic Modications in ALL$402,250
R01 · FY2015 · CA · contact PI
Targeting to Epigenetic Modications in ALL$390,183
R01 · FY2014 · CA · contact PI
Molecular pathogenesis of MLL-AF4 leukemias$345,179
R01 · FY2014 · CA · contact PI
Targeting to Epigenetic Modications in ALL$378,115
R01 · FY2013 · CA · contact PI
Molecular pathogenesis of MLL-AF4 leukemias$334,504
R01 · FY2013 · CA · contact PI
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS$477,230
P01 · FY2012 · CA · contact PI
Targeting to Epigenetic Modications in ALL$402,250
R01 · FY2012 · CA · contact PI
Molecular pathogenesis of MLL-AF4 leukemias$350,219
R01 · FY2012 · CA · contact PI
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS$470,757
P01 · FY2011 · CA · contact PI
Molecular pathogenesis of MLL-AF4 leukemias$347,535
R01 · FY2011 · CA · contact PI
Comprehensive Phenotypic Comparison of Normal and Cancer Stem Cells$1,702,016
RC2 · FY2010 · CA
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS$536,418
P01 · FY2010 · CA · contact PI
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL$371,859
P01 · FY2010 · CA · contact PI
Molecular pathogenesis of MLL-AF4 leukemias$355,690
R01 · FY2010 · CA · contact PI
Comprehensive Phenotypic Comparison of Normal and Cancer Stem Cells$1,723,218
RC2 · FY2009 · CA
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS$526,079
P01 · FY2009 · CA · contact PI
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL$364,604
P01 · FY2009 · CA · contact PI
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS$510,801
P01 · FY2008 · CA · contact PI
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL$354,060
P01 · FY2008 · CA · contact PI
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL$350,594
P01 · FY2007 · CA · contact PI
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL$257,099
P01 · FY2006 · CA · contact PI
MLL Gene Regulation in Hematopoiesis and Leukemia$66,379
K08 · FY2006 · CA · contact PI
MLL Gene Regulation in Hematopoiesis and Leukemia$132,759
K08 · FY2005 · CA
MLL Gene Regulation in Hematopoiesis and Leukemia$132,759
K08 · FY2004 · CA
MLL Gene Regulation in Hematopoiesis and Leukemia$132,759
K08 · FY2003 · CA
MLL Gene Regulation in Hematopoiesis and Leukemia$66,380
K08 · FY2002 · CA
MLL Gene Regulation in Hematopoiesis and Leukemia$132,759
K08 · FY2001 · CA